ClinicalTrials.gg
CompletedNCT02685462Updated Nov 24, 2017

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

A Phase 1 interventional study of Rosuvastatin and Atorvastatin in Healthy, sponsored by Tobira Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-24.

Sponsored by Tobira Therapeutics, Inc. (part of AbbVie) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, Open-Label, 3-Period, Single-sequence, Drug-drug Interaction Study in Healthy Subjects to Assess the Effect of Cenicriviroc on the Pharmacokinetics (PK) of HMG-CoA Reductase Inhibitors [Rosuvastatin (ROS), Atorvastatin (ATO) and Simvastatin (SIM)], Caffeine and Digoxin

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Tobira Therapeutics, Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.

First submitted before Tobira Therapeutics, Inc. became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be informed of the nature of the study and have provided written informed voluntary consent.
  • Have a ≥ 18.0 and ≤ 35.0 kg/m2.
  • Be in good general health with no abnormalities based on medical history, physical examination, clinical laboratory evaluations (clinical chemistry, hematology, urinalysis), and 12-lead that, in the opinion of the Investigator, would affect subject safety.
  • Be able to communicate effectively with the Investigator and other study center personnel and agree to comply with the study procedures and restrictions.

Exclusion criteria

Exclusion Criteria:

  • Any disease or condition that might affect drug absorption, metabolism, or excretion, or cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease, as determined by the Investigator and, if necessary, the Sponsor's Medical Monitor.
  • History of stomach or intestinal surgery, except for fully healed appendectomy and/or cholecystectomy which will be allowed.
  • Clinically significant illness or clinically significant surgery within 4 weeks before the administration of study medication.
  • History of GERD, heartburn, or nausea more than once a month, or any similar symptoms requiring the regular use of antacids, or any use of H2 histamine blockers or proton-pump inhibitors over the past 3 months.
  • History of achlorhydria, pernicious anemia, or peptic ulcers over the past 6 months.
  • Known or suspected or allergic reaction to any of the components of CVC, ROS, ATO, SIM, Digoxin or Caffeine tablets.
  • History of , with the exception of cured basal cell or squamous cell carcinoma of the skin.
  • If female, is pregnant or breast feeding, or has a positive pregnancy test result prior to the first dose of study medication.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Group 1 (Rosuvastatin)

    Group 1 (12 subjects) will receive Rosuvastatin on Days 1 and 13.

    Drug: Rosuvastatin

  • Active comparator
    Group 1 (Digoxin)

    Group 1 (12 subjects) will receive Digoxin on Days 1 and 13.

    Drug: Digoxin

  • Active comparator
    Group 1 (Caffeine)

    Group 1 (12 subjects) will receive Caffeine on Days 1 and 13.

    Drug: Caffeine

  • Active comparator
    Group 2 (Atorvastatin)

    Group 2 (12 subjects) will receive Atorvastatin on Days 1 and 13.

    Drug: Atorvastatin

  • Experimental
    Cenicriviroc

    Subjects in Group 1 and Group 2 will receive Cenicriviroc on Days 3-12. Subjects in Group 3 will receive Cenicriviroc on Days 2-12.

    Drug: Rosuvastatin · Drug: Atorvastatin · Drug: Simvastatin · Drug: Digoxin · Drug: Caffeine

  • Active comparator
    Group 3 (Simvastatin)

    Group 3 (12 subjects) will receive Simvastatin on Days 1 and 12.

    Drug: Simvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Assessment of ROS, ATO and Digoxin alone and in the presence of CVC, as measured by maximum plasma concentration (Cmax)

    Time frame: Days 1 and 13

  2. Pharmacokinetic Assessment of SIM alone and in the presence of CVC, as measured by maximum plasma concentration (Cmax)

    Time frame: Days 1 and 12

  3. Pharmacokinetic Assessment of Caffeine alone and in the presence of CVC, as measured by maximum plasma concentration (Cmax)

    Time frame: Days 1 and 13

  4. Pharmacokinetic Assessment of ROS, ATO and Digoxin alone and in the presence of CVC, as measured by minimum plasma concentration (Cmin)

    Time frame: Days 1 and 13

  5. Pharmacokinetic Assessment of ROS, ATO and Digoxin alone and in the presence of CVC, as measured by area under the plasma concentration-time curve (AUC)

    Time frame: Days 1 and 13

  6. Pharmacokinetic Assessment of SIM alone and in the presence of CVC, as measured by minimum plasma concentration (Cmin)

    Time frame: Days 1 and 12

  7. Pharmacokinetic Assessment of SIM alone and in the presence of CVC, as measured by area under the plasma concentration-time curve (AUC)

    Time frame: Days 1 and 12

  8. Pharmacokinetic Assessment of Caffeine alone and in the presence of CVC, as measured by minimum plasma concentration (Cmin)

    Time frame: Days 1 and 13

  9. Pharmacokinetic Assessment of Caffeine alone and in the presence of CVC, as measured by area under the plasma concentration-time curve (AUC)

    Time frame: Days 1 and 13

Secondary outcomes

  1. Evaluation of Adverse Events

    Evaluate adverse events

    Time frame: 23 days

  2. Changes from Baseline in Clinical Laboratory Tests

    Evaluate changes from baseline in clinical laboratory tests including serum chemistry, and hematology

    Time frame: Baseline and 23 days

  3. Changes from Baseline in 12-lead ECGs

    Evaluate changes from baseline in 12-lead ECGs

    Time frame: Baseline and 23 days

  4. Changes from Baseline in Vital Signs

    Evaluate changes from baseline in vital signs, including blood pressure and pulse rate

    Time frame: Baseline and 23 days

  5. Changes from Baseline in Physical Examinations

    Evaluate changes from baseline in physical examinations

    Time frame: Baseline and 23 days

07

Study locations

1 site
  • Miami, Florida, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Feb 2016, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2016
First posted
Feb 18, 2016
StartActual
Jan 31, 2016
Primary completionActual
Feb 23, 2016
CompletionActual
Feb 23, 2016
Last update
Nov 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02685462
Responsible party
Sponsor
First posted
Feb 18, 2016
Start date
Jan 31, 2016
Primary completion
Feb 23, 2016
Completion
Feb 23, 2016
Last update
Nov 24, 2017

Study contacts

Millie Gottwald, PharmD
study director · Tobira Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Atorvastatin · Simvastatin · Digoxin · Caffeine

Start the discussion